in combination with KEYTRUDA® (pembrolizumab) and chemotherapy for first-line treatment of metastatic non-squamous non-small ...
Thursday announced positive data from INSIGHT-003 Phase I trial, evaluating the addition of Eftilagimod alpha or ...
Jemperli plus chemotherapy demonstrated superior overall survival ... Keytruda group. A first-line treatment combination of ...
Immutep (IMMP) stock climbed 11% Thursday after the company reported positive data from two clinical trials of its drug candidate eftilagimod alpha, or efti. Read more here.
in combination with KEYTRUDA and chemotherapy for first-line treatment of metastatic non-squamous non-small cell lung cancer patients. Key data: These results compare favourably to the 22.0-month ...
Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...
The company is paying China-based biotech LaNova Medicines $588 million for the kind of dual-pronged antibody drug that ...
Immutep's INSIGHT-003 Phase 1 trial reports promising survival data for 1L NSCLC treatment using eftilagimod alpha, Keytruda, ...
Germany-based BioNTech got into the space before the gold rush that was unleashed in September by the news that Akeso and ...
The 22nd Annual Winter Lung Cancer Conference, January 31-February 2, 2025, will cover advances in NSCLC and SCLC treatment.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback